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Abstract
Background: Intracranial malignant solitary fibrous tumor (MSFT) is extremely rare. The authors report a case of
MSFT of the right occipital lobe with a rapid recurrence and bilateral lung, multiple bone metastasis.
Case presentation: The patient was a 25-year-old male presenting with headache, nausea and visual disturbances
without obvious cause. Three times right-side occipital craniotomies were performed and two times postoperative
conformal radiotherapy were administered within one year. 4 months after the third time of right-side occipital
craniotomy, the patient felt right chest pain and neck pain. Positron emission tomography/computed tomography
(PET/CT) showed tumor recurrence of the right occipital lobe and bilateral lung metastasis, multiple bone metastasis
including: vertebrae, libs, the left iliac wing, sacrum, the right ischium and upper parts of both femurs. Ultrasound
guided puncture biopsy of left-side back of the neck and CT guided puncture biopsy of the third lumbar vertebra
were performed. General sample showed grayish white or grayish red with irregular shape. Histopathologically, the
tumor was composed of areas of alternating hypercellularity and hypocellularity with spindle-shaped cells, which
arranged as fascicular, storiform pattern or patternless pattern, with intervening irregular eosinophilic collagen bundles.
Some areas showed hemangiopericytoma-like perivascular pattern and perivascular hyalinization. Tumor cells were
pleomorphic with mitotic counts of more than 4 per 10 high power fields and showed coagulative necrosis.
Immunohistochemically, tumor cells were diffusely positive for vimentin and CD99, focal positive for CD34, bcl-2
and Actin. Ki-67 labelling index was more than 40 %. The final pathological diagnosis was MSFT of the right
occipital lobe, metastatic MSFT of left-side back of the neck and the third lumbar vertebra.
Conclusion: The MSFT of the right occipital lobe with recurrence and bilateral lung, multiple bone metastasis is
extremely rare. Although intracranial MSFT is extremely rare, it should be considered in the differential diagnosis.
Definite diagnosis depended mainly on pathological morphology and immunohistochemistry. The prognosis of
MSFT is poor due to recurrence and metastasis. Complete resection of intracranial MSFT is difficult, and carful
follow-up is needed.
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Background
Solitary fibrous tumor (SFT) is a rare spindle cell
tumor of mesenchymal origin and was first differenti-
ated from mesothelioma in 1931 as primary neo-
plasms of the pleura [1]. Most SFT occur in the
pleural cavity, however, it can be found throughout
the body. The exact incidence in the central nervous
system (CNS) is not clear, but is reported to be low
[2]. Meanwhile, the diagnosis of intracranial SFT can
be difficult because of its rarity or histological and
radiological resemblance to other more common
brain tumors, such as meningioma or hemangioperi-
cytoma. Unlike the clinical behavior of thoracic SFT,
of which 37 % were malignant, it has been well
known that the vast majority (more than 94 %) of
SFT involving CNS are benign and seldom recur or
metastasize [3]. Since Ng HK et al. first reported a
case of metastatic SFT of the meninges in 2000, 10
additional definite cases have been published in the
literature (see Table 1) [4–14]. Report on a malignant SFT
(MSFT) of the right occipital lobe is extremely rare. Here
we report a very rare case of MSFT of the right occipital
lobe with a rapid recurrence and metastasis.
Case presentation
A 25-year-old male was referred to our hospital with
progressive right chest pain and neck pain on March
2014, 4 months after the third time of right-side occipi-
tal craniotomy. Initially, he presented with headache,
nausea and visual disturbances without obvious cause on
December 2012. Magnetic resonance imaging (MRI) re-
vealed intracranial tumor apoplexy of right occipital lobe
at local hospital. First right-side occipital craniotomy
was performed on 22th December 2012. Postoperation
histopathology revealed spindle cell tumor, anaplastic
meningioma was a preferred diagnosis. Then he com-
plained of repeat headaches. Follow-up MRI showed a
recurrence of tumor in the same location. The second
and third open surgery was performed successively on
21th November 2013 and 31th December 2013. Postop-
erative conformal radiotherapy was administered for two
times at doses of 54Gy and 46Gy on13th March 2013
and 17th January 2014, respectively. All these treatments
were performed at local hospital. After he was admitted
to our hospital, positron emission tomography/com-
puted tomography (PET/CT) showed tumor recurrence
of the right occipital lobe (Fig. 1a), several massive or
Table 1 Clinicopathological features of intracranial malignant solitary fibrous tumors
Report Age/Sex Location Histology Follow-up
Ng et al. 2000 [4] 55/F posterior fossa/cerebellum cellular pleomorphism, no mitoses in PT;
3–4 mitoses/10HPFs in RT, the same Ki-67
LI of 3 %
3 recurrences over 10years, metastasis to
the soft tissues and lungs
Barron et al. 2001 [5] 61/F frontal hypercellularity, marked pleomorphism,
4 mitoses/10 HPFs
10 months (postoperative radiation herapy
given)
Martin et al. 2001 [6] 71/F dura around the sagittal
sinus
marked pleomorphism, 6 mitoses /10
HPFs
death 1 month after the diagnosis
Kim et al. 2004 [7] 55/M posterior fossa hypercellularity and more than 4 mitoses/
10HPFs, pleomorphism, hemorrhage, and
necrosis
9 years,disseminated to the spine, lung,
and liver
Miyashita et al. 2004 [8] 63/F falcotentorial the MIB-1 LI increased from less than 1 %
in the PT to 13 % in the latest tumor
several recurrences over 15 years,
dissemination to the cerebrospinal fluid
Ogawa et al. 2004 [9] 70/F meninge Ki67 LI and mitosis rates were 3.1 ± 1.2 %
and less than 1/10HPF in the PT and
16.1 ± 6.4 % and 6/10HPF in the last (5th) one
4 recurrences over 26 years, metastasis to
the right lung and focal invasion into the
cerebellum
Pizem et al. 2004 [10] 60/F dura-based, left frontal the mitoses increased from less than 1/10HPF
in the PT to 16/10HPF in the latest tumor
4 recurrences over a 30-year period
Lawlor et al. 2008 [11] 77/M dural-based, left parietal invasion into the sagittal sinus, 19 mitoses/
10HPFs, marked amianthoid fibre
deposition
not known
Hu et al. 2009 [12] 54/M dural-based, left occipital hypercellularity, rare mitoses in PT, >20 mitoses/
10 HPFs in RT
died 16 month later due to recurrence
and metastasis to bilateral lungs
Zhang et al. 2010 [13] 49/F pineal region hypercellularity, 5 mitoses/10HPFs, and MIB-1
LI (7.3 ± 1.8 %)
10 months (postoperative radiotherapy
not performed)
Choi et al. 2011 [14] 39/F left occipital lobe hypercellularity, pleomorphism, Ki-67 LI
increased from 10 % (average, 1 %) in PT to
25 % in RT with infiltrative brain invasion and
15 mitoses/10HPFs
recurrences over a 6-months period
M male, F female, HPF, high-power field, LI, labeling index, PT, primary tumor, RT, recurrent tumor
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nodular shadows were seen in both lungs, the biggest le-
sion size was 5.0 cm × 5.1 cm × 5.5 cm (Fig. 1b). The
average SUV values were 4.0 in PET scan, with the max-
imum SUV values was 7.3. Many nodular and patchy
thick radioactive lesions were seen in the left attach-
ments of the 5th cervical and the 7th thoracic vertebrae
(Fig. 1c), the right attachments of the 1st, 2nd and 5th
thoracic vertebrae (Fig. 1b and c), the left 3rd and 6th
lateral ribs, the left 6th rear rib, the right 5th and 9th
rear ribs (Fig.1c), the right attachments of the 1st and
4th lumbar vertebrae (Fig. 1b), the 5th lumbar vertebral
body, the left iliac wing, the sacrum, the right ischium
and the upper parts of both femurs. The average SUV
value was 4.9, with the maximum SUV value was 8.1.
Bone destructions were seen in these lesions under CT
scan. Ultrasound guided puncture biopsy of left-side
back of the neck and CT guided puncture biopsy of the
third lumbar vertebra were performed. Biopsy samples
of left-side back of the neck and the third lumbar verte-
bra showed grayish white or grayish red with irregular
shapes. Microscopic findings showed the tumor was
composed of atypical cells arranged as fascicular, storiform
or patternless pattern with intervening irregular hyalinzed
collagen bundles (Fig. 2a). Hypercellularity or hypocellular-
ity, perivascular hyalinization and hemangiopericytoma-
like pattern were seen in some areas (Fig. 2b and Fig. 2c).
Coagulative necrosis and increased mitotic activity (>4 mi-
toses/10HPF) were noted in the tumor (Fig. 2c and Fig. 2d).
Fig. 1 PET/CT findings upon admission. (a) Tumor recurrence of the right occipital lobe. (b) Hyper-metabolic foci at the lower right lung and the
vertebrae. (c) Hyper- metabolic foci at the vertebrae and ribs
Fig. 2 Photomicrographs of the tumor of left-side back of the neck and the third lumbar vertebra. (a) The patternless architecture with intervening
irregular hyalinzed collagen bundles (H&E, ×100). (b) Hypercellularity or hypocellularity and perivascular hyalinization can be seen (H&E, ×100). (c)
Coagulative necrosis and hemangiopericytoma-like pattern were shown (H&E, ×100). (d) Cellular atypia and atypical mitosis were shown (H&E, ×400).
(e) Tumor cells were diffusely positive for CD99 (immunostain, ×200). (f) Tumor cells were focal positive for CD34 (immunostain, ×400). (g) Tumor cells
were focal positive for BCL-2 (immunostain, ×400). (h) Most tumor cells showed Ki-67 labeling index of 40 % (immunostain, ×200)
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Immunohistochemically, tumor cells were diffusely posi-
tive for Vimentin and CD99 (Fig. 2e), focal positive for
CD34 (Fig. 2f), Bcl-2 (Fig. 2g) and Actin, negative for CK,
EMA, Desmin, CD117, GFAP, PR and S-100. Ki-67 index
was more than 40 % (Fig. 2h), consistent with MSFT.
Pathologic examination was performed on the HE slides
of the right occipital lobe tumor made by former local
hospital. Similar morphological change and the same im-
munohistochemistry phenotype were found. With these
features, final pathological diagnosis is MSFT of the right
occipital lobe and metastatic MSFT of left-side back of
the neck and the third lumbar vertebra.
Discussion
Although SFT occurs mainly in the mediastinum and
visceral pleura, in accordance with previous studies,
approximately 30 % of SFT arise in any extrathoracic
locations, including the CNS [15]. Since the first SFT
case was reported in 1931 by Klemperer and Rabin, it
was not until 1996 that the first CNS SFT, located at the
meninges, was identified as a distinct entity by Carneiro
et al. [16]. The exact origination of CNS SFT remained
under controversy. In the CNS, SFTs are usually dura-
based, meningioma-like masses and are known to arise
from the ubiquitous CD34-positive dendritic interstitial
cells of meningeal coverings without meningothelial dif-
ferentiation [17]. The new World Health Organization
classification of tumors of the CNS includes SFT among
the mesenchymal nonmeningothelial tumors. It is of
interest that most intracranial SFTs seem to be dura-
based, whereas two-thirds of spinal SFTs lack a dural
attachment [2]. Currently it is more inclined to consider
they are derived from vascular mesenchymal cells [17, 18].
Due to the rarity of mesenchymal interstitial tissue in
CNS, SFT is a rare tumor of CNS.
SFT in the CNS most occurred in the posterior fossa
and spine as well as along spinal nerve rootlets [2].
However, SFT occurrence in brain parenchymal and in-
traventricular locations has also been rarely described.
CNS SFTs occur across all ages with a peak incidence in
the fifth and sixth decades of life with near equal gender
distribution. A few cases have been described in chil-
dren. In the current case, the patient was a 23-year
old man at the onset of disease. Clinical symptoms
and signs of SFT at presentation depend on the loca-
tion of the tumor and the involved organs or tissues.
In Fargen’s review, most SFT in the CNS presented
with headache (50 %) followed by gait imbalance
(22 %), weakness (19 %), visual loss (19 %), cranial
nerve dysfunction (17 %), nausea and vomiting (13 %)
and altered mental status or confusion (12 %). It is
noteworthy that the current patient presented with
rare intracranial hemorrhage (ICH) and similar pres-
entation only was described in 6 literatures [3]. In
addition, an association of approximately 4-5 % of
pleural SFTs with Doege–Potter syndrome, a rare
paraneoplastic syndrome resulting in hypoglycemia
from secretion of insulin-like growth factors 2 was
not reported in any CNS SFT cases [3, 15].
MSFT showed rapid local recurrence and distant
metastasis. Based on the new World Health Organization
(WHO) classification of tumors of the CNS published in
2007 and WHO classification of tumors of soft tissue and
bone published in 2013, necessary criterions suggestive of
the malignant potential of SFTs include hypercellularity,
more than 4 mitoses/10 HPFs, variable cytological atypia,
tumor necrosis, and/or infilitrative margins, among which
mitoses seem to be most prognostic [2, 19]. Some pathol-
ogists have suggested that the size of a SFT (bigger than
10cm) is one of the best indicators of malignancy [20].
Currently, there are no criteria for determining malig-
nancy with tumor size in cerebral SFTs. In addition,
approximately 8 % of the cases demonstrated “atypical fea-
tures” based upon brain or bone invasion, marked pleo-
morphism or high mitotic indices [3]. However, Fargen et
al. think it is important to note that above-mentioned
atypical features in no way suggest an intermediate classi-
fication of SFT between benign and malignant and may
merely reflect an increased malignant potential [3]. Even
the tumor with benign histopathologic change and intact
capsule may develop recurrence, malignant transform-
ation and delayed seeding of the CSF space. While
our case showed important malignant evidence such
as: obviously nuclear atypia, numerous mitoses, ne-
crosis and infiltrative margins. These histological fea-
tures were consistent with MSFT.
Most intracranial SFT seem to demonstrate a dural
attachment and are usually mistaken for meningioma
either radiologically and surgically. Intra-parenchymal
non-dural-based SFTs are extremely rare in cranial com-
partment. As in the current case, first postoperation
histopathology revealed a spindle cell tumor, tend to be
anaplastic meningioma. Therefore, it is possible that the
real frequency of CNS MSFT has been underestimated.
Clinical and imaging features of CNS SFTs are rela-
tively nonspecific and resemble to both meningiomas
and hemangiopericytomas, which makes preoperative
diagnosis difficult. Definite diagnosis mainly depends on
careful examination of histological and immunohisto-
chemical features. WHO classification for tumors of soft
tissue treats hemangiopericytoma and SFT as a continu-
ous spectrum of neoplasia, and many lesions that were
called hemangiopericytomas prior to 1990 could now be
called SFT [3, 15, 19]. Morphologically, SFT is generally
characterized by alternating hypercellularity and hypo-
cellularity with spindle cells intervening with irregular
hyalinzed collagen bundles showing a pattern-less archi-
tecture and a focal hemangiopericytoma-like perivascular
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pattern riched in staghorn vasculature. However, our
case showed mainly hypocellularity due to the nature
of puncture tissue. Immunohistochemically, SFT are
diffusely positive for CD34, while MSFT are weak-
ened, patchy positive for CD34, which make it diffi-
cult to tell MSFT apart from meningiomas. CD34 is
not specific for SFTs, as weak and usually patchy
staining may be visualized in meningiomas, neuro-
fibromas, and hemangiopericytomas. At this moment,
combination of CD34 with CD99 and BCL-2 is neces-
sary for differential diagnosis. Positivity for CD99 and
bcl-2 is found in more than half of all cases of SFTs,
and strongly stained with the Vimentin is also com-
mon. SFTs are usually negative for the S-100, GFAP,
EMA, cytokeratin, or vascular antigens. Recent re-
searches validate the diagnostic utility of a novel
marker, nuclear expression of STAT6, in distinguish-
ment of SFT from histologic mimics [15]. Moreover,
the identification of the NAB2-STAT6 fusion gene
can provide important diagnostic information, even in
formalin-fixed and paraffin-embedded tissue or when
biopsy material is limited [21]. In addition, compared
with CD34, ALDH1 expression had a specificity and
positive predictive value of 100 % for the diagnosis of
SFT [22, 23].
Surgery is the preferred treatment and achieves ex-
cellent local control for SFT, however, complete resec-
tion of intracranial MSFT is difficult. The prognosis
is most likely dependent upon the extent of complete
resection rather than histologic grading [2, 3, 15]. Re-
currence occurred commonly in cases involving in-
complete excision. It is clear that gross total resection
(GTR) is superior to subtotal/partial resection (STR)
in treatment of CNS SFT, with a nearly 16-fold in-
creased odds of recurrence seen in patients undergo-
ing only STR [3]. Hence, careful follow-up is needed,
especially when GTR cannot be achieved. Some
scholars suggested intraoperative pathologic examin-
ation of CNS SFTs to exclude the residual of tumor
at incisal margin. In these cases, adjuvant chemother-
apy or radiotherapy may play a role in prevention of
recurrence. However, no studies have demonstrated
the role of radiotherapy in improving long-term prog-
nosis till now and the number of patients who under-
went adjuvant chemotherapy is too small to evaluate
any possible benefit [2]. A recent study suggests that
Gamma Knife radiosurgery (GKRS) is a feasible adjunct
for treating SFT [24]. The current patient exhibited
malignant features regarding impossibility of complete
resection, rapid recurrence, distant metastasis and histo-
pathological changes. Unfortunately, postoperative radio-
therapy is of no effect to him. Adjuvant chemotherapy
had been administered to the patient after accurate diag-
nosis was made and treatment continues till now.
Conclusion
In conclusion,the authors report here a rare case of MSFT
of the right occipital lobe with a rapid recurrence and bi-
lateral lungs, multible bone metastasis. Although intracra-
nial MSFT is extremely rare, it should be considered in
the differential diagnosis of tumors in CNS, and carful
follow-up is needed. Definite diagnosis depended mainly
on pathological morphology and immunohistochemistry.
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